AP Healthcare Inc.

KOSDAQ:A109960 Stock Report

Market Cap: ₩83.0b

AP Healthcare Past Earnings Performance

Past criteria checks 4/6

AP Healthcare has been growing earnings at an average annual rate of 51.8%, while the Biotechs industry saw earnings growing at 12.4% annually. Revenues have been declining at an average rate of 13.1% per year. AP Healthcare's return on equity is 9.8%, and it has net margins of 214.4%.

Key information

51.8%

Earnings growth rate

44.5%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate-13.1%
Return on equity9.8%
Net Margin214.4%
Last Earnings Update31 Mar 2024

Recent past performance updates

We Believe Aprogen Healthcare & Games' (KOSDAQ:109960) Earnings Are A Poor Guide For Its Profitability

Mar 21
We Believe Aprogen Healthcare & Games' (KOSDAQ:109960) Earnings Are A Poor Guide For Its Profitability

Recent updates

We Believe Aprogen Healthcare & Games' (KOSDAQ:109960) Earnings Are A Poor Guide For Its Profitability

Mar 21
We Believe Aprogen Healthcare & Games' (KOSDAQ:109960) Earnings Are A Poor Guide For Its Profitability

Revenue & Expenses Breakdown

How AP Healthcare makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A109960 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2415,43133,07835,560781
31 Dec 2316,0074,30425,009794
30 Sep 2314,23222,977-2,439605
30 Jun 2312,81019,004-2,437400
31 Mar 2311,46619,707-2,829208
31 Dec 229,5982,4316,0460
30 Sep 229,0036,7062,9006
30 Jun 228,9805,1153,0284
31 Mar 228,9893,8533,6110
31 Dec 218,4162,6504,0200
30 Sep 218,5901,4284,2530
30 Jun 218,8446,4112,5810
31 Mar 219,06412,0682,4470
31 Dec 2010,31911,0842,3970
30 Sep 2012,7848,4852,6510
30 Jun 2015,3084,2595,1000
31 Mar 2018,1582,6515,2750
31 Dec 1921,901-6,7556,4990
30 Sep 1924,284-10,9595,7830
30 Jun 1922,5533435,1120
31 Mar 1920,728-1,7114,7880
31 Dec 1817,5808,6863,7980
30 Sep 1814,14111,4486,5460
30 Jun 1814,604-1,1246,9870
31 Mar 1814,004-2,6937,1460
31 Dec 1711,242-3,8636,7530
30 Sep 179,119-14,5906,9620
30 Jun 176,321-16,5646,53618
31 Mar 175,302-18,9497,147-1
31 Dec 169,821-22,41111,19818
30 Sep 1611,177-10,2289,35032
30 Jun 1612,132-9,1659,40538
31 Dec 1511,117-2,5564,83697
30 Sep 1414,778-3,5323,998264
30 Jun 1416,853-4,1464,603264
31 Mar 1419,771-3,6394,592245
31 Dec 1320,704-3,6684,898214
30 Sep 1319,737-8574,6010
30 Jun 1319,439-1,0243,9830

Quality Earnings: A109960 has a large one-off gain of ₩68.4B impacting its last 12 months of financial results to 31st March, 2024.

Growing Profit Margin: A109960's current net profit margins are higher than last year .


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: A109960 has become profitable over the past 5 years, growing earnings by 51.8% per year.

Accelerating Growth: A109960's earnings growth over the past year (67.8%) exceeds its 5-year average (51.8% per year).

Earnings vs Industry: A109960 earnings growth over the past year (67.8%) exceeded the Biotechs industry 13.4%.


Return on Equity

High ROE: A109960's Return on Equity (9.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.